Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:50523 |
Name | adult T-cell leukemia/lymphoma |
Definition | A T-cell acute leukemia that results_in abnormal increase of lymphocytes, derives_from T-cells, has_material_basis_in Human T-lymphotropic virus 1 (HTLV-1), which is transmitted_by sexual contact, transmitted_by contaminated needles used by intravenous-drug users, and transmitted_by breast feeding. The infection results_in_formation_of skin lesions. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia acute leukemia acute lymphoblastic leukemia T-cell acute lymphoblastic leukemia adult T-cell leukemia/lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
NRAS G13V | 3144 | adult T-cell leukemia/lymphoma | sensitive | detail... |
NRAS G13D | 3144 | adult T-cell leukemia/lymphoma | sensitive | detail... |
FBXW7 positive | JQ1 | adult T-cell leukemia/lymphoma | predicted - sensitive | detail... |
FBXW7 W425R | JQ1 | adult T-cell leukemia/lymphoma | resistant | detail... |
FBXW7 W425R | Birabresib | adult T-cell leukemia/lymphoma | resistant | detail... |
FBXW7 S462P | JQ1 | adult T-cell leukemia/lymphoma | resistant | detail... |
FBXW7 S462P | Birabresib | adult T-cell leukemia/lymphoma | resistant | detail... |
FBXW7 H468R | JQ1 | adult T-cell leukemia/lymphoma | resistant | detail... |
FBXW7 H468R | Birabresib | adult T-cell leukemia/lymphoma | resistant | detail... |
FBXW7 S462P | JQ1 + PLX8394 | adult T-cell leukemia/lymphoma | sensitive | detail... |
FBXW7 S462P | JQ1 + Ulixertinib | adult T-cell leukemia/lymphoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01712659 | Phase II | Ruxolitinib | Ruxolitinib for Adult T-Cell Leukemia | Terminated | USA | 0 |
NCT02580552 | Phase I | MRG-106 | Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL | Completed | USA | 0 |
NCT02588651 | Phase II | Brentuximab vedotin | A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) | Active, not recruiting | USA | 0 |
NCT02631746 | Phase II | Nivolumab | Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma | Completed | USA | 0 |
NCT02689453 | Phase I | Alemtuzumab + rhIL-15 | Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) | Completed | USA | 0 |
NCT02732275 | Phase I | DS-3201b | DS-3201b in Participants With Lymphomas | Active, not recruiting | USA | 1 |
NCT02737046 | Phase II | Interferon alpha-2b Peginterferon alfa-2b Belinostat + Zidovudine | Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma | Active, not recruiting | USA | 0 |
NCT03075553 | Phase II | Nivolumab | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | Terminated | USA | 0 |
NCT03081910 | Phase I | CD5 CAR-T cells Cyclophosphamide + Fludarabine | Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) | Recruiting | USA | 0 |
NCT03264131 | Phase II | Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone | BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma | Active, not recruiting | USA | 0 |
NCT03829540 | Phase I | CD4CAR | CD4CAR for CD4+ Leukemia and Lymphoma | Recruiting | USA | 0 |
NCT04185220 | Phase I | Mogamulizumab + rhIL-15 | Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome | Completed | USA | 0 |
NCT04283097 | Phase I | KPG-818 | Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects | Recruiting | USA | 0 |
NCT04334174 | Phase II | Brentuximab vedotin | Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas (BRENTICON-T) | Withdrawn | USA | 0 |
NCT04569032 | Phase II | Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone | A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CZE | 0 |
NCT04639843 | Phase I | Azacitidine + Doxorubicin + Duvelisib + Romidepsin | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma | Withdrawn | USA | 0 |
NCT04703192 | Phase II | DS-3201b | Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 3 |
NCT04747236 | Phase II | Pralatrexate Belinostat Azacitidine + Romidepsin Gemcitabine Romidepsin | A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL) | Recruiting | USA | 0 |
NCT04771572 | Phase I | LP-118 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | Recruiting | USA | 0 |
NCT04848064 | Phase I | Cyclophosphamide + Fludarabine Mogamulizumab | Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma | Recruiting | USA | 0 |
NCT04984837 | Phase II | Gemcitabine + Oxaliplatin Gemcitabine + Lacutamab + Oxaliplatin | Study of Lacutamab in Peripheral T-cell Lymphoma | Recruiting | FRA | ESP | DEU | BEL | 0 |
NCT05006664 | Phase II | Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone | Brentuximab Vedotin in Combination With CHEP in Patient With PTCL | Unknown status | CZE | 0 |
NCT05010005 | Phase I | Duvelisib + Ruxolitinib | A Study of Ruxolitinib and Duvelisib in People With Lymphoma | Active, not recruiting | USA | 0 |
NCT05065866 | Phase I | Azacitidine + Duvelisib | Duvelisib in Combination With CC-486 in Lymphoid Malignancy | Active, not recruiting | USA | 0 |
NCT05371054 | Phase Ib/II | Prednisone + Venetoclax + VIP152 | Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies | Recruiting | USA | 0 |
NCT05377827 | Phase I | WU-CART-007 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT05565417 | Phase Ib/II | IMT-009 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | Recruiting | USA | 0 |
NCT05967416 | Phase I | SIRPant-M | Phase 1, Open-Label Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | Recruiting | USA | 0 |
NCT05983965 | Phase I | Tazemetostat Acalabrutinib + Tazemetostat | Study of Tazemetostat in Lymphoid Malignancies | Recruiting | USA | 0 |
NCT06492304 | Phase Ib/II | CTX131 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | Recruiting | USA | 0 |